
|Articles|June 13, 2007
Ophthalmic interventions offer best value gains
Therapeutic interventions, in particular for neovascular age-related macular degeneration (AMD) offer a better degree of value than any other treatment right across the field of healthcare.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: Long-term follow-up in paediatric gene therapy
2
Macular laser picks up speed: The technology accelerating retinal therapies
3
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
4
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight
5












































